Immunotherapy For The Treatment Of Colorectal Tumors: Focus On Approved And In-clinical-trial Monoclonal Antibodies

dc.creatorFrancoso
dc.creatorAlex; Simioni
dc.creatorPatricia Ucelli
dc.date2017
dc.date2017-11-13T13:15:25Z
dc.date2017-11-13T13:15:25Z
dc.date.accessioned2018-03-29T05:52:57Z
dc.date.available2018-03-29T05:52:57Z
dc.identifierDrug Design Development And Therapy. Dove Medical Press Ltd, v. 11, p. 177 - 184, 2017.
dc.identifier1177-8881
dc.identifierWOS:000391768600001
dc.identifier10.2147/DDDT.S119036
dc.identifierhttps://www.dovepress.com/immunotherapy-for-the-treatment-of-colorectal-tumors-focus-on-approved-peer-reviewed-article-DDDT
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/327355
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1364380
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionColorectal cancer is considered a disease of the elderly population. Since the number of geriatric patients continues to rise, monoclonal antibody therapy is the most promising therapy in the recent research. Presently, the monoclonal antibodies most frequently used in the treatment of colorectal tumors are bevacizumab, cetuximab, panitumumab, and ramucirumab. Bevacizumab is a monoclonal antibody that acts on VEGF. Cetuximab and panitumumab act on EGFR. Ramucirumab binds directly to the ligand-binding pocket of VEGFR-2 to block the binding of VEGF-A, VEGF-C, and VEGF-D. These monoclonal antibodies, alone or in association with radiotherapy or chemotherapy, are presenting good results and are increasing patient survival, despite the side effects. Due to the limited number of molecules available, several studies are trying to develop new monoclonal antibodies for the treatment of colorectal tumors. Among those being studied, some recent molecules are in phase I and/or II trials and are yielding advantageous results, such as anti-DR5, anti-Fn14, anti-IGF-1R, anti-EGFR, anti-NRP1, and anti-A33 antibodies. This has been successful in reducing side effects and in treating nonresponsive patients.
dc.description11
dc.description177
dc.description184
dc.descriptionSao Paulo Research Foundation (FAPESP) [2013/20258-2, 2016/19321-0]
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.languageEnglish
dc.publisherDove Medical Press Ltd
dc.publisherAlbany
dc.relationDrug Design Development and Therapy
dc.rightsaberto
dc.sourceWOS
dc.subjectMonoclonal Antibodies
dc.subjectColorectal Tumor
dc.subjectBevacizumab
dc.subjectCetuximab
dc.subjectPanitumumab
dc.subjectRamucirumab
dc.titleImmunotherapy For The Treatment Of Colorectal Tumors: Focus On Approved And In-clinical-trial Monoclonal Antibodies
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución